Bangor Savings Bank cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,291 shares of the company’s stock after selling 130 shares during the period. Bangor Savings Bank’s holdings in Johnson & Johnson were worth $1,570,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Americafirst Capital Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth $103,000. Lenox Wealth Management Inc. increased its position in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. increased its position in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth $127,000. Institutional investors own 65.19% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.94% on Friday, reaching $114.13. The company had a trading volume of 3,433,340 shares. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The firm has a market capitalization of $310.49 billion, a price-to-earnings ratio of 20.03 and a beta of 0.75. The company’s 50-day moving average price is $116.14 and its 200-day moving average price is $118.35.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 18th. The company reported $1.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.66 by $0.02. The firm had revenue of $17.80 billion for the quarter, compared to analysts’ expectations of $17.71 billion. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.49 EPS. On average, analysts predict that Johnson & Johnson will post $6.72 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a $0.80 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 annualized dividend and a yield of 2.80%. Johnson & Johnson’s payout ratio is presently 56.64%.
JNJ has been the topic of a number of research reports. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective on the stock in a report on Monday, August 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective on the stock in a report on Friday, August 5th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, September 7th. RBC Capital Markets set a $133.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a report on Wednesday, November 9th. Finally, Credit Suisse Group AG restated a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a report on Monday, September 19th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $120.79.
In other news, Director Charles Prince bought 875 shares of the business’s stock in a transaction on Friday, October 21st. The shares were purchased at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.11% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.